ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

Michael Schultze

Director of Real-World Evidence & Safety Data Analytics

Foto - Michael Schultze

Dr. Michael Schultze leads a dedicated team of Real-World Evidence (RWE) experts in designing and implementing secondary data-driven non-interventional studies.

Alongside his managerial responsibilities for the RWE secondary data department, Michael is responsible for the development of medical algorithms and the interpreting of big medical data sets of secondary data projects. These projects cover diverse topics such as Epidemiology, HEOR and Safety, and a broad range of therapy areas.

His interdisciplinary experience combines the three areas of expertise essential for secondary data-related studies: medical expertise, advanced project management skills, and a profound understanding of working with Real-World Data (RWD). With his in-depth knowledge of current opportunities, challenges, needs, and limitations of RWE and RWD, Michael is also ideally placed to consult regarding RWE in general and different study designs to bridge the growing need for leading-edge secondary data methodologies with classical post-authorization safety and efficacy studies.

Michael holds a doctorate and a state examination degree in Veterinary Medicine, both from the Ludwig Maximilian University of Munich, Germany.

Publications

Schultze Michael, Zema C., Carroll R., Hurst M., Borchert J., Zhong Y., Krause T., Bluhmki T., Partington H., Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany. 2022;
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Gairy Kerry, Levy R., Economic Burden of Organ Damage in Systemic Lupus Erythematosus: Results From a German Claims Analysis. DGRh Kongress. 2021; 10.3205/21dgrh064.
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Levy R., Gairy Kerry, The Burden of Organ Damage Among Patients With Systemic Lupus Erythematosus in Germany. International Congress on Systemic Lupus Erythematosus. LUPUS & CORA 2021. 2021;
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. Value in Health (22). 2019; 10.1016/j.jval.2019.09.2645.